Top Ten Hot Topics in China’s Biopharmaceutical Industry in 2021
[Summary Description]
In 2021, the biopharmaceutical sector witnessed a series of landmark developments: government‑led policies were rolled out one after another; COVID‑19 vaccines and specialized therapeutics were successively developed and brought to market; two CAR‑T therapies received approval, marking the inaugural year of cell therapy in China; and the country’s first “off‑the‑shelf” CAR‑NK product was granted clinical trial authorization.
The Year of the Ox, shrouded in the shadow of the COVID‑19 pandemic, has finally come to a close. As the frontline force in combating the pandemic, China’s biopharmaceutical sector has surged with remarkable vigor, bringing another year to a triumphant end amid sweeping changes and dynamic progress.

In 2021, the biopharmaceutical sector witnessed several landmark developments: a series of supportive national policies were introduced; COVID‑19 vaccines and specialized therapeutics were successively developed and brought to market; two CAR‑T therapies received approval, marking the inaugural year of cell therapy in China; and the country’s first “off‑the‑shelf” CAR‑NK product was granted clinical trial authorization.
In addition, China’s biopharmaceutical transactions, investment and financing activities, and corporate IPOs have continued to expand, reaching new historical highs.
Amid the festive greetings of the New Year, let’s take ten minutes to revisit the top ten highlights of China’s biopharmaceutical industry, and reflect on the proud moments we’ve shared and helped shape.
01. “14th Five-Year Plan for the Development of the Biopharmaceutical Industry”
On March 12, 2021, the Outline of the 14th Five-Year Plan for National Economic and Social Development of the People’s Republic of China and the Long-Range Objectives for 2035 was officially released, setting out the state’s policy priorities for the 14th Five-Year Plan period and the long-term goals for economic and social development over the next 15 years, while also identifying the key areas of focus for the pharmaceutical industry in the years ahead.
In the biopharmaceutical sector, the Outline explicitly calls for fostering integrated innovation between biotechnology and information technology, accelerating the development of industries such as biopharmaceuticals, bio‑breeding, biomaterials, and bioenergy, and scaling up and strengthening the bioeconomy. It also emphasizes establishing a number of national laboratories in key areas like biotechnology, reorganizing national key laboratories, and building a well‑structured, highly efficient laboratory system.
Subsequently, local governments across the country have successively unveiled their respective 14th Five-Year Plans for the biopharmaceutical sector. Among these, Shanghai’s “14th Five-Year Plan for the Development of the Biopharmaceutical Industry,” as a leading force in the field, has drawn particular attention.
Shanghai’s development plan clearly states that the city will pursue a strategic direction of “high-end, intelligent, and international” for the biopharmaceutical industry. Through five major initiatives and ten key projects, Shanghai aims to accelerate the establishment of a globally influential innovation hub and a world-class biopharmaceutical industrial cluster. During the 14th Five-Year Plan period, Shanghai will support the market launch of 15 domestically developed Class I innovative drugs and 35 innovative medical devices, while adding 25 newly listed companies.
By 2025, six industrial parks each with an output value exceeding RMB 10 billion will have been established, and Shanghai’s biopharmaceutical industry is expected to surpass RMB 1 trillion in scale.
02. A flurry of new industry policies and the “Guidance Principles for Clinical Development of Antitumor Drugs Oriented Toward Clinical Value”
2021 marked the inaugural year of the 14th Five-Year Plan. During this period, the pharmaceutical industry witnessed a flurry of policy releases, with the number of policies surging compared to 2020. Several key policies are expected to exert significant influence on the development of the biopharmaceutical sector in the years ahead.
On January 13, 2021, the National Medical Products Administration issued the “Guidance on Acceptance and Review of Changes to Biological Products (Trial),” comprehensively standardizing the requirements for accepting and reviewing changes to biological medicinal products.
On December 20, 2021, the “Procedures for Drug Registration Inspection (Trial)” was issued, setting forth clear requirements for drug registration review and applications for market approval. On the same day, the “Technical Guidance Principles for Clinical Pharmacology Studies of Innovative Drugs” were also released, primarily addressing issues related to pre‑marketing clinical pharmacology studies of innovative drugs.
In addition, throughout the year, guidelines and technical requirements were issued for a wide range of drug categories across multiple therapeutic areas, including biosimilars, chemical drugs, improved new drugs, gene therapies, cell therapies, intravenous anesthetics, COVID‑19–related chemical drugs, and COVID‑19 neutralizing antibodies. Specific guidance has been developed for both nonclinical and clinical studies, further refining regulatory oversight and enhancing the level of standardization and approval efficiency in drug development.
In contrast to the relatively low‑key rollout of earlier policies, the release on November 19, 2021, of the “Guiding Principles for Clinical Development of Antitumor Drugs Oriented Toward Clinical Value” sent shockwaves through the industry, sparking widespread controversy.
As early as July 2, 2021, the CDE issued a notice soliciting public comments on the “Guiding Principles for Clinical Development of Antitumor Drugs Oriented Toward Clinical Value.” On the day of the release, the shares of two leading CROs—WuXi AppTec and Tigermed—plummeted by 7.71% and 6.13%, respectively.
In the newly released R&D guidelines, it is emphasized that drug development should be “patient‑centered and clinically value‑driven.”
It explicitly states that, during clinical trials, first, subjects should be offered the best available standard-of-care treatment or drug; second, the highest priority in new‑drug development should be to provide patients with superior therapeutic options. In particular, the BSC changes regarding the selection of clinical control groups have directly reduced the likelihood of “me‑too” drugs being approved, thereby impacting the number of product‑development projects initiated by biotech firms and decreasing the volume of orders that CXO companies can secure. All of this underscores the regulatory authorities’ clear stance against “me‑worse” products.
Industry consensus holds that the release of these guiding principles challenges the current state of domestic R&D, which has been plagued by intense “involution,” and directly reshapes pharmaceutical companies’ R&D strategies. From a market perspective, while the policy will undoubtedly exert some influence on the future development of the innovative‑drug and CXO sectors, its core value—placing patient needs at the forefront, prioritizing clinical value, and addressing unmet clinical needs—is both commendable and far‑reaching.
03. Domestic vaccines have been added to the World Health Organization’s Emergency Use Listing.
At 23:00 on May 7, 2021, the World Health Organization held a press conference, during which Director-General Tedros Adhanom Ghebreyesus announced that the inactivated COVID‑19 vaccine developed by China National Pharmaceutical Group’s Beijing Institute of Biological Products had been added to its Emergency Use Listing.
On June 1, 2021, the World Health Organization held a press conference, during which Director-General Tedros Adhanom Ghebreyesus announced the inclusion of the inactivated COVID‑19 vaccine developed by China’s Sinovac Biotech on its Emergency Use Listing.
Inclusion on the WHO Emergency Use Listing (EUL) signals to national regulatory authorities that a product is safe and effective, paving the way for countries to expedite regulatory approval processes for importing and managing the vaccine.
Sinopharm’s COVID‑19 vaccine has been approved for registration and market launch or emergency use in 70 countries and regions as well as by international organizations. More than 100 countries and international organizations have expressed procurement needs, with domestic and international supplies exceeding 200 million doses, and vaccinations now reaching populations in 196 countries.
04. The inaugural year of cell therapy in China
On June 22, 2021, axicabtagene ciloleucel injection (trade name: Yikaida), a CAR‑T cell therapy product developed by Fosun Kite, a joint venture under Fosun Pharma, received approval from the National Medical Products Administration of China for the treatment of adult patients with relapsed or refractory large B‑cell lymphoma (r/r LBCL). This marked the first approved CAR‑T cell therapy in China, breaking ground and ushering in the inaugural year of cell therapy in the country.
On September 1, 2021, Reziluocel Injection, a CD19‑targeted CAR‑T cell therapy developed by Shanghai Jacobio Biotechnology Co., Ltd. based on Juno Therapeutics’ JCAR017, was approved for market launch.
In the field of cell therapy, China ranks second only to the United States in the number of CAR‑T clinical studies. As of March this year, there were a total of 718 CAR‑T clinical trials worldwide, with China having officially initiated 148 of them. The successive approvals of Yaoming JUNO’s relakiretucel injection and Fosun Kite’s axicabtagene ciloleucel injection mark the domestic CAR‑T market’s entry into a phase of rapid growth.
The two CAR‑T therapies have been classified as “exorbitantly priced drugs,” with list prices of RMB 1.2 million per infusion and RMB 1.29 million per infusion, respectively. Although Yikaida passed the initial review in the 2021 national medical insurance drug negotiation process, its high price—deemed inconsistent with the “basic coverage” principle underlying such negotiations—has prevented it from advancing to the national reimbursement drug list following expert evaluation.
05. China’s first “spot‑trade‑type” CAR‑NK cell therapy IND has been approved.
On November 11, 2021, the Center for Drug Evaluation of the National Medical Products Administration of China approved the clinical trial application for a “chimeric antigen receptor NK cell (CAR‑NK) injection targeting mesothelin (MSLN) for the treatment of advanced epithelial ovarian cancer,” developed by Guojian Chengnuo Biotechnology (Beijing) Co., Ltd. (hereinafter referred to as CAR‑NK injection).
This product is the first domestically developed “off-the-shelf” allogeneic CAR‑NK therapy to receive formal approval from the Center for Drug Evaluation, marking a new milestone in the research of immune cell–based therapies for solid tumors.
06. Insulin-Specific Volume-Based Procurement
In November 2021, the sixth round of national centralized bulk procurement of pharmaceuticals was officially launched. Unlike the previous five rounds, this initiative was a targeted procurement program, with insulin becoming the first biologic to be included in nationwide volume‑based purchasing. The insulin procurement encompassed both second‑ and third‑generation insulins, divided into six product categories—three each for rapid‑acting, basal, and premixed formulations—resulting in an average price reduction of 48%.
As the largest category of antidiabetic drugs in China’s market, the insulin segment in Chinese public hospitals reached nearly RMB 27 billion in 2020. Against a backdrop where imported brands have long dominated the domestic market, the results of this centralized procurement revealed that seven domestic pharmaceutical companies—including Ganlee Pharmaceutical, Federal Pharmaceutical, and Tonghua Dongbao—secured contracts.
Several securities firms have released research reports arguing that, with the implementation of the national centralized procurement of insulin, domestic pharmaceutical companies are expected to see a modest increase in market share, and the substitution of imported products by domestic alternatives is likely to accelerate.
The insulin-specific centralized procurement is reshaping the nearly RMB 30 billion market landscape. Looking ahead to 2022, whether biologics will be included in centralized procurement may well be the topic of greatest concern.
07. Medical Insurance Negotiations and the Plunge in Prices of Sky-High-Cost Drugs
On December 3, 2021, the “National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2021)” was released. Notably, the 2021 drug list included seven medications for rare diseases, among them two “exorbitantly priced” drugs: nusinersen sodium injection, marketed by Biogen for the treatment of spinal muscular atrophy, and agalsidase alfa concentrate for injection, developed by Takeda for Fabry disease.
On September 4, 2021, media reports indicated that Xiaohua, who is under two years old, was diagnosed with spinal muscular atrophy (SMA) at the Children’s Hospital of the Second Affiliated Hospital of Xi’an Jiaotong University.
During the course of treatment, doctors administered an expensive, disease-specific medication—nusinersen injection. As early as 2020, this drug had already sparked widespread controversy due to its price tag of 700,000 yuan per dose.
According to the hospital bill for Xiaohua, the total cost over four days amounted to 553,639.2 yuan, with 550,177.2 yuan allocated to Western medicines. The exorbitant price of a rare‑disease drug—Biogen’s nusinersen sodium injection, which costs as much as 550,000 yuan—has once again made headlines.
Following the release of the 2021 National Reimbursement Drug List, a video capturing an on‑site medical insurance negotiation trended on social media and went viral on WeChat Moments. In the clip, after an hour and a half of eight rounds of intense price bargaining—during which several company representatives repeatedly stepped away to confer—the drug nusinersen injection was finally agreed upon at 33,000 yuan per vial, down from its initial offer of 53,600 yuan per vial.
Watching a sky-high drug priced at 700,000 yuan per injection make its way into the national medical insurance catalog at a steep discount, we’re still moved by the words of the medical‑insurance negotiation experts: “No small group should be left behind.”
High‑cost drugs for rare diseases have been included in China’s national medical insurance catalog for the first time, shedding light on the pressing issue of access to medications for rare diseases that has drawn widespread public attention. Ensuring adequate access to treatments for rare diseases remains a long and arduous task, and advancing the diagnosis and treatment of these conditions in China will require coordinated efforts from the government, industry, and civil society.
08. China’s first domestically developed “specialty drug” for COVID-19 has been unveiled.
In 2021, two SARS‑CoV‑2 variants, Delta and Omicron, emerged in May and November, respectively. Amid a severe epidemic situation, on December 8, 2021, the National Medical Products Administration granted emergency approval for the registration applications of BRII‑196, an anti‑SARS‑CoV‑2 monoclonal antibody combination therapy developed by Tengsheng Biopharmaceuticals’ subsidiary, Tengsheng Huachuang Pharmaceutical Technology (Beijing) Co., Ltd., and BRII‑198, another anti‑SARS‑CoV‑2 monoclonal antibody.
This is the first domestically approved combination therapy for COVID‑19 based on neutralizing antibodies with independent intellectual property rights in China. In accordance with relevant provisions of the Drug Administration Law and under the special approval procedure for drugs, the National Medical Products Administration conducted an emergency review and approval, granting authorization for the combined use of the two aforementioned medications in the treatment of patients infected with the novel coronavirus (COVID‑19).
From research to approval, this innovative COVID‑19 drug took just over one year. Tengsheng Huachuang has proudly showcased China’s speed and strength to the world, representing the Chinese biopharmaceutical industry.
09. Massive, High-Profile License-Out Deal
On August 8, 2021, Rongchang Bio and Seattle Genetics entered into a global exclusive licensing agreement for vidisitozumab. Vidisitozumab is China’s first original antibody–drug conjugate (ADC) to receive dual Breakthrough Therapy designations from both the U.S. FDA and China’s NMPA.
Seattle Genetics has obtained global development and commercialization rights to vidisitozumab outside the territories of Rongchang Bio, while Rongchang Bio will retain the rights to conduct clinical development and commercialize the product in Asia (excluding Japan and Singapore).
Rongchang Bio stands to earn up to $2.6 billion in potential revenue from this deal. On the day the transaction was announced, Rongchang Bio’s shares surged more than 40% in early trading.
Just four months after Rongchang Bio’s record-breaking licensing deal, on December 20, BeiGene announced an agreement with Novartis to jointly develop, manufacture, and commercialize BeiGene’s investigational TIGIT inhibitor, ociperlimab, in North America, Europe, and Japan.
In addition, the two parties have agreed to grant BeiGene the rights to market, promote, and sell five approved Novartis oncology drugs in designated regions within China, with a total transaction value of approximately US$2.895 billion, setting a new record for overseas licensing by a Chinese biopharmaceutical company.
10. Biopharmaceutical investment and financing are booming.
In 2021, investment and financing in China’s biopharmaceutical sector continued to grow at a rapid pace, driven by the pandemic. High‑profile products, projects, and companies have consistently drawn intense discussion and attention from industry professionals. Consider these achievements:
In 2021, biopharmaceutical financing reached 522 deals, with a total value of RMB 111.358 billion, up 53.1% and 26.0%, respectively, from 2020.
Among the year’s financing deals, key projects in the innovative drug sector included Omer Pharma, which raised RMB 300 million, and Jiayue Pharma, which secured over RMB 300 million.
Key projects in the biopharmaceutical R&D pipeline include (Shodi: USD 100 million; Genuine Biotech: USD 100 million).
Key project in the R&D of antibodies and molecular enzymes (ABclonal, RMB 1.2 billion);
Key project in the field of precision oncology (Jiyingjia, RMB 750 million);
Key project in the field of synthetic microbiology (Lanjing Microbiology, RMB 430 million);
Key projects in the clinical-stage biopharmaceutical sector (Zhengtengkang Biotech: USD 75 million; Credence Biologics: USD 68 million).
In terms of IPOs, the Chinese biopharmaceutical sector added 121 new companies, an increase of over 75% compared with 2020. By exchange, 50 companies listed on the Shanghai Stock Exchange, 30 on the Hong Kong Stock Exchange, 27 on the Shenzhen Stock Exchange, 5 on the U.S. NASDAQ, 5 on the New Third Board (NEEQ), and 4 on the Beijing Stock Exchange.
The biopharmaceutical sector has consistently seen rising levels of IPO activity and investment, with strong capital inflows and the dedicated efforts of industry professionals driving its rapid growth, dynamism, and boundless potential.
Previous page
Previous page
A warm welcome to Vice Mayor Lin Keqing for his visit and guidance at Dongfang Baitai.
On October 24, 2016, Beijing Vice Mayor Lin Keqing and his delegation visited Beijing Dongfang Baitai Biotechnology Co., Ltd. and Baitai Bio-pharmaceutical Co., Ltd., conducted an in-depth review of the companies’ R&D progress, inspected the production workshops on-site, and engaged in cordial discussions.
Leave a Message Online Online Message